Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis.
The acquisition of immunity following subclinical or resolved infection with the intracellular parasite Leishmania donovani suggests that vaccination could prevent visceral leishmaniasis. The characteristics and in vitro stimulating capability of the recombinant proteins expressed by previously identified clones on the basis of their capacity to stimulate an indigenously established Leishmania-specific cell line leading to high level of IFN-gamma suggested these to be potential candidates for immunoprophylaxis against leishmaniasis. In this study, we investigated the protective efficacy of purified recombinant proteins from two of the identified cDNA clones along with the adjuvant MPL, in a hamster model of experimental leishmaniasis. We demonstrate here that the immunization of animals with one of the recombinant proteins (rF14) having 97% similarity to C1 clone of L. chagasi ribosomal protein gene P0 (rLiP0) along with MPL provided partial protection against the virulent challenge of L. donovani. The absence of antigen-specific lymphoproliferative responses in these immunized animals may be responsible for the lack of complete and long-lasting protection.
Bhardwaj
Suvercha
S
Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India.
Vasishta
R K
RK
Arora
Sunil K
SK
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis; D000953:Antigens, Protozoan / Q000276:immunology; D006224:Cricetinae; D016207:Cytokines / Q000096:biosynthesis; D004195:Disease Models, Animal; D005260:Female; D006099:Granuloma / Q000209:etiology; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000096:biosynthesis; D007893:Leishmania donovani / Q000276:immunology*; D007898:Leishmaniasis, Visceral / Q000517:prevention & control*; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives; D008099:Liver / Q000469:parasitology / Q000473:pathology; D008213:Lymphocyte Activation; D008297:Male; D008647:Mesocricetus; D009573:Nitrites / Q000378:metabolism; D009929:Organ Size; D016052:Protozoan Vaccines; D013154:Spleen / Q000276:immunology / Q000469:parasitology / Q000473:pathology; D013481:Superoxides / Q000378:metabolism; D014614:Vaccines, Synthetic
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D016207:Cytokines; D007074:Immunoglobulin G; D008050:Lipid A; D009573:Nitrites; D016052:Protozoan Vaccines; D014614:Vaccines, Synthetic; D013481:Superoxides; C048436:monophosphoryl lipid A